Nebu~Flow is an innovative medical device company expert in respiratory drug delivery with a vision to develop the next generation of nebulisers to deliver fragile and hard-to-nebulise drugs with potentially life-changing results.
The British Lung Foundation estimates that 10,000 people are diagnosed with a lung disorder every week in the UK. This is why MedTech company Nebu~Flow is on a mission to unlock the delivery of the next generation of inhaled drugs for patients with respiratory disorders.
Respiratory diseases are known as the leading causes of death and disability in the world, with estimated clinical costs of €400bn/year in Europe*. To contribute to the tackling of this, Nebu~Flow is developing the next generation of nebulisers to enable efficient delivery of hard-to-nebulise drugs to the lungs.
Nebu~Flow collaborates with world-renowned specialists to develop its unique nebuliser, and its technology has the potential to help deliver cutting-edge treatments including in areas like gene therapy, while improving outcomes for patients with life-limiting conditions such as cystic fibrosis.
In 2022, the worldwide inhalable drug market was estimated to be worth over $43 billion**. Moreover, the global nebuliser market is valued at over $1 billion***, and Nebu~Flow’s nebuliser has been developed to provide a number of advantages over existing technologies.
With this in mind, Nebu~Flow secured an oversubscribed £1.7 million investment round led by Foresight Williams Technology alongside SIS Ventures, Science Creates Ventures and Ascension Life Fund. The new investment will help the company to commercialise and deliver its next generation respiratory pharmaceuticals.
“Our technology enables efficient respiratory delivery of a wider range of drugs that are hard to nebulise. Many of these drugs, like biologics, are potentially lifesaving. We are pleased to have the support of Foresight and our other investors, whose ambitions for the business are very much aligned with our own.”
Dr Elijah Nazarzadeh, CEO and co-founder, Nebu~Flow (pictured)
*European Lung White book (published by ERS):https://www.erswhitebook.org
**The global inhalable drugs market is valued at over USD 43 billion in 2022: https://www.verifiedmarketresearch.com/product/pulmonary-drug-delivery-systems-market/
***The global nebuliser market size was valued at USD 1.04 billion in 2021: https://www.grandviewresearch.com/industry-analysis/nebulizers-market
Beta Bugs secures £1.72m to scale up sustainable insect farmingRead more about Beta Bugs secures £1.72m to scale up sustainable insect farming
Microplate Dx secures £2.5m to develop rapid antibiotic testing technologyRead more about Microplate Dx secures £2.5m to develop rapid antibiotic testing technology
SIS Ventures joins EIS AssociationRead more about SIS Ventures joins EIS Association